Evidence map›Paper›PMID 32669020›Full record

ArticleThe Journal of neuropsychiatry and clinical neurosciences2021

The Functionality, Evidence, and Privacy Issues Around Smartphone Apps for the Top Neuropsychiatric Conditions.

Mia T Minen, Ariana Gopal, Gabriella Sahyoun, Eric Stieglitz, John Torous

Abstract read
In one paragraph

Article in The Journal of neuropsychiatry and clinical neurosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mia T MinenDepartments of Neurology and Population Health, New York University Langone Health (Minen); City College of New York (Gopal); Barnard College, New York (Sahyoun); and Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston (Torous).
Ariana GopalDepartments of Neurology and Population Health, New York University Langone Health (Minen); City College of New York (Gopal); Barnard College, New York (Sahyoun); and Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston (Torous).
Gabriella SahyounDepartments of Neurology and Population Health, New York University Langone Health (Minen); City College of New York (Gopal); Barnard College, New York (Sahyoun); and Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston (Torous).
Eric StieglitzDepartments of Neurology and Population Health, New York University Langone Health (Minen); City College of New York (Gopal); Barnard College, New York (Sahyoun); and Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston (Torous).
John TorousDepartments of Neurology and Population Health, New York University Langone Health (Minen); City College of New York (Gopal); Barnard College, New York (Sahyoun); and Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston (Torous).

Funding

Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
Progressive Muscle Relaxation for Chronic Pain in an Acute Care SettingK23AT009706 · NCCIH · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MINEN, MIA · 2018 to 2022
$923k
NCATS NIH HHS UL1 TR001445NCCIH NIH HHS K23 AT009706
6 · The paper itself

Abstract

objectiveThere are more than 325,000 health-related smartphone applications (apps) on the market. To better understand the apps currently on the market for the five most disabling neuropsychiatric conditions, the authors conducted a study investigating their intended uses (target population and intervention), the data collected, and any privacy policies.

methodsThis was a cross-sectional study of apps for the five most disabling neuropsychiatric conditions per the World Health Organization: stroke, migraine, depression, Alzheimer's disease and dementia, and anxiety. Up to 15 apps in the U.S. Google Play and Apple app stores were selected based on the following prespecified inclusion criteria: the app appeared in the top 50 search results, offered intervention or tracking capabilities, and listed the condition in the app title or description. Exclusion criteria were <$5.00 to purchase, solely motor versus cognitive-based intervention, or designed for use by caregivers or health care providers. Data abstracted included function, behavior change rewards, and information about intervention, privacy policy, and payment.

resultsEighty-three apps were reviewed (stroke, N=8; migraine, N=25; Alzheimer's disease and dementia, N=8; depression, N=7; anxiety, N=14; apps targeting depression and anxiety, N=21). Sixty-nine percent of apps had an intervention component, 18% were deemed evidence based, 77% had a privacy policy, 70% required payment for access to all features, and 19% rewarded user behavior changes.

conclusionsMost apps on the market targeted migraine, depression, and anxiety and contained interventions, although most of the interventions did not appear to be evidence based. Additionally, although most apps had privacy policies, lay people may have difficulty understanding these policies due to their complexities.

Indexed as

Mobile ApplicationsPrivacyAlzheimer DiseaseCross-Sectional StudiesDepressionEvidence-Based PracticeHumansMigraine DisordersSmartphoneStrokeAlzheimer’sAnxietyDementiaDepressionMigraineSelf-Management ToolsSmartphone ApplicationsStroke

Identifiers

PMID32669020
PMCPMC8670295

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.